We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer.
- Authors
Saltalamacchia, Giuseppe; Torrisi, Rosalba; De Sanctis, Rita; Masci, Giovanna; Miggiano, Chiara; Gaudio, Mariangela; Benvenuti, Chiara; Jacobs, Flavia; Gerosa, Riccardo; Santoro, Armando; Zambelli, Alberto
- Abstract
Based on the unprecedented results observed in recent clinical trials, antibody-drug conjugates (ADCs) have revolutionized the treatment algorithm of metastatic breast cancer (mBC). The strategy of sequencing different ADCs in other lines of therapy is highly attractive, but the proportion of patients who have undergone such a strategy in the context of published clinical trials is still limited, especially for modern ADCs. HER2-positive disease is primarily managed with a sequence of different ADCs. Historically, trastuzumab emtansine (T-DM1) has been the most commonly used ADC for both early and metastatic HER2-positive disease. Considering the recent evidence related to trastuzumab deruxtecan (T-DXd), it is expected to assume the role of the main ADC in our clinical practice. Herein, we report a retrospective analysis of the sequence of different ADCs relying on available published data from clinical trials.
- Subjects
ANTIBODY-drug conjugates; METASTATIC breast cancer; BREAST cancer; CLINICAL trials; TRASTUZUMAB
- Publication
Biomedicines, 2024, Vol 12, Issue 3, p500
- ISSN
2227-9059
- Publication type
Article
- DOI
10.3390/biomedicines12030500